<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04558892</url>
  </required_header>
  <id_info>
    <org_study_id>5/8952 (443)</org_study_id>
    <nct_id>NCT04558892</nct_id>
  </id_info>
  <brief_title>Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome.</brief_title>
  <acronym>ENOX-inNS</acronym>
  <official_title>Assessment of Coagulation Disorders and of Enoxaparin's Anti-Xa Activity, When Used for Thromboprophylaxis, in Severe Nephrotic Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Military Institute of Medicine, Poland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Military Institute of Medicine, Poland</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to test the hypothesis that enoxaparin efficacy is reduced in severe&#xD;
      nephrotic syndrome. Another purpose is to compare two dosing regimens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nephrotic syndrome (NS) is a rare clinical condition characterized by proteinuria exceeding&#xD;
      &gt;3.5 g/24h, hypoalbuminemia, dyslipidemia and edema and is associated with hypercoagulable&#xD;
      state. In severe cases, with serum albumin ≤2.5 g/dL, the risk of venous thromboembolic&#xD;
      events (VTE) is particularly high, and pharmacological prophylaxis is recommended. However,&#xD;
      there is a limited evidence of its efficacy and optimal dosing.&#xD;
&#xD;
      The study is designed as 3 arms clinical trial, with 2 study groups and a single control&#xD;
      group. The study groups will include patients with severe NS parallelly, alternately assigned&#xD;
      (1:1) into two enoxaparin dosing regimens. The control group will consisted of individuals&#xD;
      without proteinuria and edema, similar in terms of age, anthropometric features and renal&#xD;
      function to NS patients, who will be administered a standard enoxaparin dose. A peak anti-Xa&#xD;
      activity at the steady state will be measured to determine the plasma concentration of&#xD;
      enoxaparin. Additional laboratory tests for markers of NS severity, renal function and&#xD;
      coagulation system proteins will be performed. The overhydration and body water compartments&#xD;
      will be assessed using bioimpedance spectroscopy technique. Nephrotic patients will be&#xD;
      followed up by 12 months to assess overt VTE and adverse events associated with enoxaparin&#xD;
      use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The primary objectives were achieved.&#xD;
  </why_stopped>
  <start_date type="Actual">October 1, 2015</start_date>
  <completion_date type="Actual">November 30, 2018</completion_date>
  <primary_completion_date type="Actual">November 30, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic enoxaparin's anti-Xa activity in nephrotic syndrome.</measure>
    <time_frame>Average: Day 3-5</time_frame>
    <description>Anti-Xa activity values ≥ 0.3 IU/mL in the steady state of enoxaparin concentration, on average between days 3 and 5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum threshold of enoxaparin's anti-Xa activity.</measure>
    <time_frame>Average: Day 3-5</time_frame>
    <description>Anti-Xa activity values ≥ 0.2 IU/mL in the steady state of enoxaparin concentration on average between days 3 and 5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of nephrotic syndrome.</measure>
    <time_frame>Day 0, Day 3-5</time_frame>
    <description>Serum or/and urinary concentration of laboratory markers of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation system protein.</measure>
    <time_frame>Day 0, Day 3-5</time_frame>
    <description>Plasma concentration or activity of secondary hemostasis system protein (clotting factors, fibrinolysis factors, regulatory molecules).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function.</measure>
    <time_frame>Day 0, Day 3-5</time_frame>
    <description>Estimated glomerular filtration rate (eGFR) calculated with simplified 4-variable Modification of Diet in Renal Disease (MDRD) formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Edema.</measure>
    <time_frame>Day 0, Day 3-5</time_frame>
    <description>Clinical evaluation of edema using 3-stages scale (I: &lt;5 kg, II: 5-10 kg, III: &gt;10 kg) at enrollment and on the day of measuring anti-Xa activity of enoxaparin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overhydration.</measure>
    <time_frame>Day 3-5</time_frame>
    <description>Overhydration measured by bioimpedance spectroscopy on the day of measuring anti-Xa activity of enoxaparin.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Venous thromboembolic events.</measure>
    <time_frame>Follow-up period of 1 year from enrollment.</time_frame>
    <description>Clinically overt episode of VTE.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events of enoxaparin.</measure>
    <time_frame>Follow-up period of 1 year from enrollment.</time_frame>
    <description>Episodes of minor and major bleeding or heparin-induced thrombocytopenia.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Nephrotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Nephrotic syndrome - fixed dose (NS-FD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Enoxaparin; Dose: 40 mg; Administration: once daily subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nephrotic syndrome - adjusted dose (NS-AD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Enoxaparin; Dose: 1 mg/kg of ideal body weight; Administration: once daily subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - fixed dose (C-FD)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Enoxaparin; Dose: 40 mg; Administration: once daily subcutaneously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <arm_group_label>Control - fixed dose (C-FD)</arm_group_label>
    <arm_group_label>Nephrotic syndrome - adjusted dose (NS-AD)</arm_group_label>
    <arm_group_label>Nephrotic syndrome - fixed dose (NS-FD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Severe NS, defined as proteinuria exceeding 3.5 g/24h or 50 mg/kg/24h and serum&#xD;
             albumin ≤2.5 g/dL;&#xD;
&#xD;
          -  eGFR ≥30 mL/min/1.73 m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) ≥40 kg/m2;&#xD;
&#xD;
          -  Low body mass (&lt;45 kg for female, &lt;57 kg for male);&#xD;
&#xD;
          -  Acute VTE;&#xD;
&#xD;
          -  Previously introduced anticoagulation (due to comorbidities);&#xD;
&#xD;
          -  Contraindications for enoxaparin;&#xD;
&#xD;
          -  Pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Matyjek, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Military Institute of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Military Institute of Medicine</name>
      <address>
        <city>Warsaw</city>
        <state>Masovian District</state>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Military Institute of Medicine, Poland</investigator_affiliation>
    <investigator_full_name>Anna Matyjek</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Nephrotic syndrome</keyword>
  <keyword>Enoxaparin</keyword>
  <keyword>Low molecular weight heparin</keyword>
  <keyword>Anti-Xa activity</keyword>
  <keyword>Antifactor Xa</keyword>
  <keyword>Venous thromboembolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

